11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron(Western General Hospital), Martine Piccart(Université Libre de Bruxelles), Richard D. Gelber(Université Libre de Bruxelles), Marion Procter(Frontier Agriculture (United Kingdom)), Aron Goldhirsch(European Institute of Oncology), Evandro de Azambuja(Université Libre de Bruxelles), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Michael Untch(Helios Hospital Berlin-Buch), Ian Smith(Institute of Cancer Research), Luca Gianni(San Raffaele University of Rome), José Baselga(Memorial Sloan Kettering Cancer Center), N. Al-Sakaff(Roche (Switzerland)), Sabine Lauer(Roche (Switzerland)), Eleanor McFadden(Frontier Agriculture (United Kingdom)), Brian Leyland‐Jones(Avera Health), Richard H. Bell(Deakin University), Mitch Dowsett(Institute of Cancer Research), Christian Jackisch(Sana Klinikum Offenbach)
Cited by 1,036Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis